 VANCOUVER, Jan. 21, 2021 GLOBE NEWSWIRE -- BetterLife Pharma Inc. BetterLife or the Company CSE: BETR OTCQB: BETRF FRA: NPAU, an emerging biotech focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, is pleased to announce that it has engaged Equilab International to manage the upcoming clinical trials for its proprietary formulation of Interferon alpha2b AP-003 in mild to moderate cases of COVID-19. 